Ken Griffin Purple Biotech Ltd. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.41 - $0.86 $13,691 - $28,719	-33,395 Reduced 57.55%	24,628 $10,000
Q1 2024 May 15, 2024	BUY	$0.58 - $0.92 $26,822 - $42,546	46,246 Added 392.68%	58,023 $38,000
Q4 2023 Feb 14, 2024	SELL	$0.78 - $1.67 $1,675 - $3,587	-2,148 Reduced 15.43%	11,777 $9,000
Q3 2023 Nov 14, 2023	SELL	$1.02 - $1.49 $32,659 - $47,708	-32,019 Reduced 69.69%	13,925 $16,000
Q2 2023 Aug 14, 2023	BUY	$1.38 - $2.05 $42,461 - $63,076	30,769 Added 202.76%	45,944 $64,000
Q1 2023 May 15, 2023	SELL	$1.36 - $2.3 $41,738 - $70,587	-30,690 Reduced 66.91%	15,175 $27,000
Q4 2022 Feb 14, 2023	BUY	$1.38 - $2.22 $63,293 - $101,820	45,865 New	45,865 $63,000

19.3K

Ticker PPBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,303,300
Market Cap $46.5M
Description
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.